November 13, 2025 • 34 mins
Mike Blue is the CEO of HistoSonics. The company recently developed a device that uses ultrasound to destroy tumors.
On today’s show, Mike talks about how a garage-built prototype became an FDA-approved machine; changing the company’s story after a failed clinical trial; and why he loves being a salesman but hates most sales pitches.
See omnystudio.com/listener for privacy information.
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:15):
Pushkin. Hey, it's Jacob. Just a quick note before we
start the show. Today, I'm hosting a new podcast in
addition to this one. The new show is called Business History,
and it's about the history of business and I think
you'll like it. If you like What's Your Problem, I
(00:36):
think you'll like Business History. The first episode is out today.
It's about Southwest Airlines, which is an amazing story. And
then starting next week we're going to have a series
on Thomas Edison, who is really a very What's Your
Problem kind of guy, made an incredible amount of technological progress,
had a really interesting life, lived at an incredible time.
So the show is called Business History. You can listen
(00:58):
to it wherever you are listening to this podcast, Please
check it out. I hope you like it. In twenty seventeen,
Mike Blue was a vice president of sales at Johnson
and Johnson and he went to see a product demonstration
at this little healthcare startup that he was interested in.
It was a small medical device company that was hoping
(01:19):
to use ultrasound in new and dramatic ways, but the
company didn't have any products on the market at the time.
Speaker 2 (01:26):
It was in a garage in Ann arbor. Literally the
office was a dozen or so engineers and they did
a product demonstration for me on the old system that
they delivered this sound energy into a tank of water.
And you see what looks like a hologram. It's the
bubble cloud and it's just suspended in the middle of
the tank and it's just millions of bubbles that are
(01:49):
colliding and collapsing, and it's just suspended there. And they
can move it faster than the eye can detect. They
can stop it, they can start it, like unparalleled control
of it. They can do anything with it. And depending
on who you are, what your lens or perspective is,
I think your mind starts to race as to what
that could mean. I thought, this is gonna be the
(02:10):
best damn sales demonstration in the history of the world.
And I thought, let's just assume it's gonna work. It's effective,
and it's safe no matter where we use it. Oh
my goodness, we're going to sell a ton of these things.
Speaker 1 (02:31):
I'm Jacob Goldstein, and this is what's your problem. My
guest today is Mike Blue. He's the CEO of a
company called Histosonics. The company is developing a technology called histotripsy.
Speaker 2 (02:43):
So many medical terms are in Greek, and so histo
is tissue and tripsy is crushing, the crushing of so
it's the crushing of tissues.
Speaker 1 (02:54):
So histo tripsy, if you speak Greek, it makes perfect sense.
Speaker 2 (03:00):
It's a mouthful for everybody else in English.
Speaker 1 (03:04):
Here's what the company has done. They've taken this histo
tripsy technology that was developed at the University of Michigan
and built a device that shoots multiple ultrasound waves into
the body. At the spot where the waves converge, they
create this cloud of tiny bubbles like the one Mic'
saw in that demo. Those tiny bubbles destroy cells, they
(03:25):
crush tissue. So, for example, you can aim the device
at a tumor inside the body, and if everything goes well,
you can use the bubble cloud to destroy the tumor.
This could be incredibly helpful, especially for tumors that don't
respond well to radiation or chemotherapy or surgery. And in fact,
in twenty twenty three, the FDA cleared the use of
(03:48):
the Histosonics device to treat tumors in the liver. Mike
and I talked a lot about the use of the
device to treat cancer and how Histosonics got there. But
we started by talking about what was happening at the
company when Mike joined in twenty seventeen. This was before
they were focused on cancer treatment, and at the time
(04:09):
they'd run a clinical trial comparing their device with surgery
to treat men with enlarged prostates. But the study found
that surgery worked better to achieve key outcomes. So you
get to the company that the prostate treatment has failed.
Is it already clear that failed? It failed to meet
(04:31):
its primary endpoint. That's the great thing about a trial.
Speaker 2 (04:34):
It is.
Speaker 1 (04:36):
Well, but also it's acceedes or it fails. I'm sticking
with fails.
Speaker 2 (04:42):
When I started and was just getting my teeth kicked
in trying to raise money, I mean, we were a
company running out of money. I mean I was a
bit crazy to take this job. I'll use your term.
We had a failed clinical trial. And you've got a
technology that, or at least a therapy that is almost
too good to be true and unbelievable. And yes, it's
worked in animals, but enough with that animal. Yes, you've
got to become You've got to become a a You've
got to grow up and be a real business.
Speaker 1 (05:03):
And my sly and primates exaggerate, right, that's the and.
Speaker 2 (05:08):
Yes, well said, I was overly confident thought with my
sales background and with an amazing therapy, I would come
in and just raise money. I got my teeth kicked
in for you know, almost two years. And the story
of histotripsy it's to go back to how we open it.
It's hard to say, like, it's not memorable, people can't
remember it, and it's too good to be true, and
(05:28):
you've got this failed clinicaltrure.
Speaker 1 (05:29):
I mean, it's just it was.
Speaker 2 (05:30):
It was hard and so I so we we flipped
the script. We totally changed. We challenged ourselves to find
a story that would resonate, and so we were building
an almost autonomous robotic surgical platform. And if you look
at the evolution of surgery, it's gone from open surgery
(05:50):
to laparoscopic to robotic to our story became we are
developing the future of completely non invasive surgery, which we are,
and robotic non invasive surgery. And the appetite for robotic
investments is incredible.
Speaker 1 (06:07):
So you changed the story, not so much on the
medical side, but on the investor side. It's not saying
so early in the conversation, you don't need to say hist.
Speaker 2 (06:16):
To tripsy, just know that we are going to complete
the evolution of surgical robotics. And so that story led
to an investment from doctor Fred Moule, who's the godfather
of robotic surgery. He was a co founder of Intuitive
Surgical and.
Speaker 1 (06:34):
Sort of the model company for your company.
Speaker 2 (06:36):
It's the poster child for robotic surgery, and he understood. Fortunately,
doctor Mole understood both the robotics of what we were
doing and the therapy.
Speaker 1 (06:47):
Was it already clear that cancer was going to be
the next sort of thing. You tried to make it work.
Speaker 2 (06:55):
So we're blessed to have this ongoing relationship with the
University of Michigan. So there's just incredible professors and researchers
and students who every day get up and work on
the next thing with histotripsy. So at that time, back
now almost ten years ago, there was work being done
(07:16):
specifically on cancers and tumors and small animals, and what
we were learning was that histotripsy is incredibly effective at
destroying cancer cells. And so now I join in January
of twenty seventeen and it's you know, Mike, what do
you think? And so we decided that abdominal tumors is
(07:39):
where we would start. They're the most commonly treated with
other quote unquote interventional devices today, liver, kidney, lung.
Speaker 1 (07:49):
There these are bad cancers to have. I mean, it's
bad to have cancer, but it's really bad to have
the worst.
Speaker 2 (07:56):
I mean liver, liver, lung, and pancreatic, pancreatic being the
worst in terms of five year survival. So we had
made that decision, and then you've got to have discussions
with the FDDA, so we you know, to understand exactly
you've got to align with them on certain things. And
so what we knew we were going to do is
build a robotic platform. We're going to automate the procedure,
(08:19):
democratize the procedure so that you don't have to go
to the absolute best in the world, and because it
can be used anywhere in the body, We're going to
build a platform that can rapidly go from each indication
or application to the next, regardless.
Speaker 1 (08:35):
Of spect You're not going to build a machine to
treat one kind of tumor as well one thing.
Speaker 2 (08:39):
We're building a thing we're building a platform that can
treat a hundred things. You just need to do the
clinical trials. And so we began to work with the
FDA on a broader approach for soft tissue, which is
very common both in interventional devices or for surgical platforms
and robotic systems. A soft tissue indication that allows the
(09:01):
physician to treat any soft tissue or solid tumor that
they deem medically necessary. That's a appropriate Well, there was
keen awareness of histotripsy and how novel it is, how
different it is your liquefying tissue. There's nothing else in
medical device or health care that does.
Speaker 3 (09:20):
This could go not as expected, and there's a different
way that each organ removes that liquification from the bodies
liquified are so in fairness, there's a different risk to
each potential organ, and they asked us to at least
start in a single organ or for a single application.
Speaker 2 (09:43):
So we chose liver based on it. You said, it's
it's still although there's lots of different modalities that are
used in the liver. For liver cancer, five year survival
rates are still less than twenty percent. They really haven't changed,
so you're throwing all this new stuff at it, but
you're still unfortunately, the majority of patients, great majority of
(10:04):
patients are not living over five years. And then, in
addition to that, we want to do in dress because
of all the different ways that you can apply a
non invasive, non toxic therapy, the opportunity is to use
histotripsy in new and novel ways to benefit patients that
just aren't being done today. And that includes the great
(10:25):
majority of patients who not just have primary liver cancer,
but have tumors in their liver that were caused by
their primary cancer.
Speaker 1 (10:37):
So you, for this initial test trial that the FDA
wants you to do, you're gonna treat tumors that are
in the liver, whether they start in the liver or
start somewhere else. You get breast cancer and then it
spreads to your liver for example.
Speaker 2 (10:50):
That's it, yep, And we're gonna we're gonna treat those
tumors and we're going to demonstrate that we can do
it safely and we can effectively destroy any tumor from
any origin that is in the liver. And that was
the primary objective or aim of the hope for Liver study,
which was our pivotal clinical study for the FDA.
Speaker 1 (11:11):
Right, so let's talk about that study, the Hope for
Liver study, Like, who was it, what was the endpoint,
what were the patients?
Speaker 2 (11:21):
So, when you're working with the FDA on designing these studies,
it is very collaborative. There are things that you want
as a company and propose and work through, and then
there are things that the agency ultimately requires a few
And because this is a new novel therapy never been
done before, especially in a cancerous tumor, they required that
(11:46):
we treat patients who were had either failed all other
treatment options or intolerable, meaning they just they just they
hadn't failed surgery or radiation, they just can't they can't
tolerate it be based on their overall condition.
Speaker 1 (12:03):
Basically people who don't have any other options, who are
typically quite so.
Speaker 2 (12:06):
So yeah, and when we set the inclusion exclusion criteria,
we had not envisioned that that would be.
Speaker 1 (12:14):
Well, that's how they do drugs, right. If you have
a new drug, then the FDA says, well, make sure
that patients have already tried the drugs that we already
know work. Right, It seems quite analogous.
Speaker 2 (12:23):
Very analogous and in some respects fair and so yeah,
so we were required to treat advanced, very advanced stage patients.
The challenge with that is that when we set our
safety goal and our efficacy goal, we set that based
on the data that's available and on and the data
(12:44):
that's available is on much healthier patients, usually earlier stage
patients with curative intent. And we didn't change the the
end points were, what the performance criteria was that we
had established. We could only change who these patients were
that we were treating. Why not, Well, that's not you
don't necessarily get to site all the rules when you're
(13:05):
negotiating with the agency, and so it's just a requirement
that we ended up having to live by.
Speaker 1 (13:09):
So just the basics of the trial, like how many patients,
what's the outcome? You know, what's the basics there.
Speaker 2 (13:17):
So we negotiated a study that would enroll I think
it was up to fifty patients. We ended up I
think we enrolled forty four and with pretty acute outcomes
both in terms of safety and efficacy.
Speaker 1 (13:34):
And what was the result, What were the results?
Speaker 2 (13:36):
So they were incredibly positive. In fact, now we've published
our one year data, and honestly, I didn't know that
a year out or two years out the data would
be very interesting at all. These were super sick patients
and again we're measuring it the performance criterias against healthier patients,
and so if you could get anywhere close at one year,
(14:00):
you know, I thought we'd be doing pretty good, but
I doubted that. But that's where we ended up. We
just published our one year follow up data on the
patients who have local tumor control, meaning meaning it's still
dead ninety percent of the time in those patients, which
rivals any other therapy that's being delivered in delivered today.
Speaker 1 (14:22):
And just to be clear, when you say it's still dead,
do you mean the whole tumor is gone. I mean
it doesn't mean they don't have cancer anymore. Right, This
doesn't like these are super sick patients. You didn't just
cure their cancer.
Speaker 2 (14:33):
Just to be clear, the aim of the study was
to show that we can safely target and destroy a
tumor and that that tumor does not come back. The
aim of the study was not to show that we're
extending their life, we're improving their overall survival, which is
obviously a really important metric in cancer care, and ultimately
we will do that.
Speaker 1 (14:51):
It's ultimately the one we care. I mean, I suppose
there's quality of life as well, but neither of these
is a clinical measure, right.
Speaker 2 (14:58):
And I would argue today now that we're a year
and a half into our true clinical experience, what I
call the real world rout the wild being used in
an unbelievable number of different ways and use cases. Improving
quality of life is probably the number one thing that
I think we're just so excited about. It's just it's unbelievable.
Speaker 1 (15:18):
I want to talk about that. I want to talk
about a lot of stuff besides the study, but just
to finish on the study, Yeah, just the dumb question
you're saying, you killed the tumor, why does the person
still have cancer?
Speaker 2 (15:29):
Because for most of the patients we treated, again based
on the requirement that the FDA established, they had lots
of tumors. They had what they call multifocal disease. So
not just two or three, we're talking half a dozen dozen.
Many of the patients had dozens of tumors and the
(15:51):
protocol allowed for the treatment of up to three. So
we know most of those patients, the great majority had
tumors beyond what we were treating.
Speaker 1 (16:03):
The one other endpoint you were monitoring was serious adverse
events related to the right. What was the outcome for that?
Speaker 2 (16:11):
Yep, I think there were three grade three or higher ctcas,
which is how one of the models they used to
score serious adverse events. So there were three of them
out of the forty four patients, which far exceeded our
primary endpoint. And again the primary end point was measured
(16:34):
against much healthier patients, so you had far fewer serious
adverse events than you would expect and are measured against
healthier patients. So incredibly excited about how safe this procedure
is in a sicker patient patient.
Speaker 1 (16:51):
I thought it was six.
Speaker 2 (16:52):
There were three that were grade three higher.
Speaker 1 (16:56):
I don't know the grade three. I just thought there
were six serious adverse device.
Speaker 2 (17:00):
The six in total.
Speaker 1 (17:02):
Thank you for going into the weeds with me. Now
we can come back out.
Speaker 2 (17:06):
Not what I expected. I love it.
Speaker 1 (17:12):
After a break, we'll come back out of the weeds.
So where are your devices in the world now? Like,
are they out there? Are people buying them? Are doctors
using them in the real world? Now?
Speaker 2 (17:33):
I mean this has been a long, long journey. A
glorious Friday, October sixth of twenty twenty three that we
finally had the email come across that awarded us at
Denovo grant or a clearance to begin commercializing the Edison
system and the use of histotripsy and the liver.
Speaker 1 (17:55):
This is the email from the FDA, an email from
the FDA.
Speaker 2 (17:59):
So we've got a gong in the building that is
called the getting Shit done gong, and we hit the
hell out of that gong and an awesome party immense
upon receiving that letter. I mean, it's just you know,
it is the pinnacle milestone for any healthcare company, and
so a first in my career. Within one hour after
(18:20):
that announcement, we had our first purchase order for an
Edison system.
Speaker 1 (18:25):
The one hour was it just waiting? Was it?
Speaker 2 (18:27):
Was?
Speaker 1 (18:27):
It just like you had the contract.
Speaker 2 (18:29):
They were waiting. We had. We had a very small
skeleton crew of sales professionals who are out socialized in
the contrast concept of histotripsy and and what it could
mean to physicians, patients and hospitals and so uh, the
Cleveland Clinic was locked and loaded and ready to claim
(18:49):
that they were the first in the world to begin
using histo tripsy for their their livertub er patients.
Speaker 1 (18:56):
And so how does the University of Michigan feel about
getting scooped on its own technology.
Speaker 2 (19:00):
Yeah, yeah, it didn't go over so well.
Speaker 1 (19:02):
Were they were they number two? Do they have one?
Speaker 4 (19:04):
Now?
Speaker 2 (19:05):
They were not number two? They were they were within
the top and now they have multiple within within.
Speaker 1 (19:13):
How many of them are out in the world now?
How many of yes?
Speaker 2 (19:16):
You know. A year and a half into commercializing, the
thought was it was almost exclusively be in the US.
We're now in the process of a scheduling delivery of
our one hundred system.
Speaker 1 (19:26):
One hundred okay, so a lot a non trivial number.
Speaker 2 (19:29):
You know, if you compare it to other historic commercial
launches of a robotic medical device or platform, we're far
exceeding expectations. And the patient demand for this is is
like nothing I've ever been a part of and what
we had hoped for. It's sad and that there's so
many patients who are told their terminal because now they
(19:51):
have tumors in their liver that can't be treated. They're
adjacent to a bile duct, they're just too large there's
just too many of them. There's no drugs that work
for these tumors once they're in their liver, and we
can treat these patients and we can do it without toxicity,
without side effects.
Speaker 1 (20:05):
I mean, there is some pain right like related with
the treatment.
Speaker 2 (20:09):
So they'll there will be discomfort because a lot of
times you're treating over the rib cage that they explain
it usually as they've done too many sit ups the
day before, like that, that sort of pain. Some of
them have flu like symptoms, which is symptomatic of potentially
the immune system being revved up. But beyond that nothing
(20:32):
like an invasive procedure or radiation therapy, you can't even
compare them.
Speaker 1 (20:38):
So if I if I walk into a room where
your device is, like, what's it look like?
Speaker 4 (20:45):
Like?
Speaker 1 (20:45):
Let's just talk about how it works. What do I
see when I walk down the room?
Speaker 2 (20:51):
Yep, you see what looks like a medical device system
with a It's pretty noticeable. It's got a pretty large
robotic arm that is used to guide the therapy. It's
got a very obvious forty two inch high fidelity touchscreen display.
So you see a cart that's I guess similar to
(21:14):
what you'd think of like an ultrasound cart. That's where
all the work is done, and then you've got a
robotic arm that comes off that that steers the histotripsy.
Because it's non invasive, it doesn't require a sterile environment,
so you definitely don't need to be in an operating room.
It doesn't even require a clean room. You can virtually
do procedures in any room. And ultimately the vision is
(21:37):
it'll be used by an incredible number of specialists or specialties.
So that's what it looks like.
Speaker 1 (21:44):
So let's say, so there's a procedure, what happens, there's
a doctor, there's a patient, like, where are they?
Speaker 2 (21:49):
What happened? Like every robotic procedure being done in the
hospital setting today, the patient usually not always anymore, but
usually under general anesthesia. The reason for that is not pain.
It's about limiting motion. So, because we're delivering this beam therapy,
we don't want the patient moving, we don't want the
(22:09):
organ moving, we don't want the tumor.
Speaker 1 (22:11):
Moving like you're targeting like a centimeter, right, I.
Speaker 2 (22:14):
Mean it's the yeah, the point on a pencil tip.
Speaker 1 (22:18):
Breathing, So does breathing mess you up?
Speaker 2 (22:20):
Right? And so where we are today treating in the liver,
finishing our study on kidney tumors, beginning our studies on
pancreatic tumors. These organs and therefore tumors move because of
the diaph the movement of the diaphragm.
Speaker 1 (22:36):
What do you do about that? Like? That isn't I mean?
Do you account for it? Do you predict where it's
going to be based on the breath?
Speaker 4 (22:43):
Like?
Speaker 1 (22:43):
How do you deal with that?
Speaker 2 (22:44):
That's why you use general anthesus because the anithesiologists then
can absolutely control motion.
Speaker 1 (22:51):
Oh so you say to the anesthesiologists, halt the breathing
for one second. I'm going to shoot the beam.
Speaker 2 (22:58):
It doesn't have to be completely still. Almost all of
them there's some motion, and we just, huh what they
call envelope around that. So we just create you know,
if you've got a one centimeter tumor, you create a
two centimeter target so that the motion of the your
targeted area still encompasses the tumor, even if even if
(23:19):
it's moving.
Speaker 1 (23:20):
So okay, so the patient's under general anesthesis, so they
don't move too much.
Speaker 2 (23:23):
Go on, Yeah, so there's still there's still and then
you watch the physician operate on that again super high
fidelity touchscreen display. There is a step to the planning
process where we send in planning pulses to seven discrete
points within the targeted area, both within the tumor and
just outside. And the reason for that is depending on
(23:48):
how much blockage there is, if it's under a rib,
if it's under a bow, or if it's completely unobstructed,
there's a different level of energy that is needed to
destroy different areas within even sometimes the same tumor, but
definitely if you're treating multiple tumors, one could be directly
under a rib totally obstructed, one could be totally unobstructed.
(24:10):
The variability then between how much energy the system needs
the delivers it can be pretty significant. And then once
they begin or initiate therapy, the robot has the ability
to dynamically change the energy requirements throughout the treated volume
based on that treatment map. So you watch that, you're
(24:31):
literally watching the physician work at the console do their
work there, and then there's a button that says enable treatment,
and once everyone agrees they've they've set the plan. The
system knows how much energy it needs to deliver and augment,
they enable therapy and then it's all visualization. It's it's
just monitoring.
Speaker 1 (24:51):
So once they enable therapy, like what happens with the
robot arm, what does it do? And like where's the
ultrasound coming out of?
Speaker 2 (24:58):
It goes to work. So it's the workhorse. It begins.
It's got these amazing it's it's so elegant to watch.
They've got incredibly fine smooth motions that are moving that.
So think of the histo tripsy cloud the size of
a grain of rice. It's super small and it's got
to go through a large volume. So it does all
(25:19):
the work moving that bubble cloud until it's completely destroyed.
Speaker 1 (25:23):
And just to be clear, it's destroying the tumor at
a cellular level, right, the reason you're not spreading the
cancer around the body.
Speaker 2 (25:31):
It's actually subcellular destruction. It's if you were to show
it to a pathologist, we show or when a pathologist
reads that liquefied tissue coming from an app they'll tell
you it's unrecognizable. There's no cellular debris. They couldn't tell
you forget about is it benign, or they can't tell
(25:52):
you if it's liver, kidney anchoras brain. It's just a
liquefied acellular debris that is unrecoible go. It's literally a goo,
even more soluble than a goo, A.
Speaker 1 (26:06):
Thin, very thin that is. And then it's done. And
then the procedure is done.
Speaker 2 (26:13):
Yeah, they awake from their anesthesia, hopefully they feel like
nothing has happened, and they go home.
Speaker 1 (26:19):
So you have this indication for any liver tumor. What
else are you working on beyond liver tumors?
Speaker 2 (26:27):
We are now realizing the vision of the researchers who
invented histor tripsy and when the company was founded, moving
as fast as we can into other clinical applications. And
so we've finished in rolling patients in our kidney tumor trial.
We will have the data back from that here shortly
(26:47):
and be submitting for histor tripsy of kidney cancer in
Q one of twenty twenty six. We've begun in rolling
patients in a pancreatic tumor trial that's being done in Barcelona, Spain.
We are working with the agency as we speak to
(27:08):
arrive on a call for the US study treating pancreatic
tumors with hista tripsy. I really do believe it's gonna
be groundbreaking.
Speaker 1 (27:15):
What are you trying to figure out now? Like, what
is a use case where you haven't kind of quite
solved all the things you need to solve to make
it work.
Speaker 2 (27:24):
There's very little clinically and technically. It's the challenges that
come with such a high growth company and adding so
many people. And I think if you I'll invite you
to visit us, I think we'll give you a demo
so we can make all this real.
Speaker 1 (27:43):
I want the demo. After you describe the demo.
Speaker 2 (27:46):
You have to have the demo. I think, you know,
I'm very proud that whomever is visiting here, they immediately
notice the people, the culture of the vibe, the tech
permeates throughout. Super innovative company with great people, smart people
but are having fun. Literally you know, change the world.
(28:09):
And so it's it's preserving that as we grow at
a unusually fast pace and at a significant number of
people moving forward, is there such an unmet clinical need
that we can address. And as I as I say
to our team we've got a town hall tomorrow, I'll
you know, I always remind them that I know we
said unusually aggressive objectives, and I will not apologize. There
(28:31):
is a patient who is suffering in every one of
the diseases that we can impact, and we have to
go faster. It's it's literally it's the first company I've
ever been with, right, I feel like we actually have
a I use this word a lot, or we have
a responsibility the faster we can move and kidney pancreas,
prostate brain diary, breast bladder. There's patients who need us
today and we won't be there in time unfortunately for
(28:52):
all of them. So it's our responsibility to go faster.
So that's kind of stuff that keeps me up at night.
Speaker 1 (29:01):
We'll be back in a minute with the lightning round.
We're going to do a sales focus lightning round because
I know that you spent your career in sales and
that was all we could figure out about you. Is
(29:22):
there anything that you had to sort of unlearn from
your life in sales to be a good CEO? Any
like habits of the sales mind that don't serve you
well as a CEO.
Speaker 2 (29:33):
So at one point in my career, before I joined
his Tosonics, obviously I really doubted I wanted to be
a CEO. I didn't know if I could get the
same gratification statis satisfication. That's not our word gratification.
Speaker 1 (29:48):
I like satisfication. That's when gratification meets satisfaction too. Actually,
the ginormous of satisfaction.
Speaker 2 (29:54):
I just didn't know if I could get that same gratification,
like the rush of I love to win. I love
closing a deal. I love to win. I hate losing
even more. And that's what you get in sales. You're
out every day competing against your peers, other companies. So
I thought coming into this I would have to temper
my excitement for the thrill of the win and the
(30:17):
hatred for the loss. But I think what's helped the
company is I haven't done that. Like, you can apply
the same winning and losing philosophies across every function within
the organization. I want to win with the FDA, I
hate losing. I hate needing to renegotiate, I hate the delay.
(30:37):
And you can literally apply that that logic across or
dispe It works everywhere.
Speaker 1 (30:45):
It works.
Speaker 2 (30:47):
Everywhere. Okay, fair enough, Look you if you bring that
to work every day, like you know, like I tell
my kids, if you find something you genuinely love a
company that you genuinely believe in, and you go out
and work your ass off every day and you compete,
Like at what I just said. And then third, and
I hope if you were to walk through this building,
what you would see is amazing human beings. Like that's recipe, Like, Yeah,
(31:10):
find something you love and you're passionate for a company
you believe in what they're doing, work your ass off,
compete to win, hate to lose, and you're a genuinely
good human being. And that's how you treat everybody. There's
really nothing else. There's nothing more to success in industry
than that.
Speaker 1 (31:27):
What's the hardest thing you ever had to sell?
Speaker 2 (31:30):
Well, I think I'm good at selling everything.
Speaker 1 (31:33):
I didn't say, what were you bad at selling?
Speaker 2 (31:35):
Like?
Speaker 1 (31:35):
I just said what was hard?
Speaker 2 (31:37):
I will so I will say this, I would make
a horrible venture capitalist, like horrible.
Speaker 1 (31:45):
Interesting. Well, in a way, they're on the buying side, right,
I mean, I'm sure they're selling themselves to the hot
founder or whatever, but.
Speaker 2 (31:52):
They're evaluating all these opportunities in which ones they're going
to invest in, and they choose one out of one
hundred to invest in. My problem is I always look
at them with the perspective or with the lens of
could I sell this? And I'm an overly confident person
that I look about just everything and say, oh, I
could sell that. And so I'd be a horrible venture
(32:14):
capitalist the heart.
Speaker 1 (32:15):
Because you'd invest in everybody because you'd be like, yeah,
sure I could sell that whatever, I'll flip it for
ten X.
Speaker 2 (32:20):
Yeah we could do we could do that. The problem
is if you're not the one doing that, then you're
relying on someone else. You don't have the control of
what they're doing day to day.
Speaker 1 (32:31):
You know.
Speaker 2 (32:31):
I Selling medical technology is hard. It's just it is.
It's just really hard. Especially in today's healthcare environment. Just
getting access into hospitals has become so complex. So it
doesn't matter whether you're selling a single use widget or
a two million dollar robotic platform. It's changing the world.
Speaker 1 (32:55):
It's by the way, is it two million dollars? I
didn't ask you how much does it cost? Is the answer?
Two million dollars.
Speaker 2 (32:59):
It's not. It's not two million dollars. But what we
generally say is it compares very favorably to the other
high end surgical robotic platforms.
Speaker 1 (33:09):
Fine, I just wanted some ballpark.
Speaker 2 (33:11):
Call it a million, million, million and a half dollars.
That's fun.
Speaker 1 (33:14):
Okay, great, last one.
Speaker 2 (33:17):
Uh.
Speaker 1 (33:18):
I'm curious as a as a person who knows sales
so well, when you're on the other end of sales,
when you're a buyer, say, when you go buy a car,
what is it like for you?
Speaker 2 (33:28):
It's bullshit.
Speaker 4 (33:29):
It's like there's nothing worse, And it's everywhere in this world,
like literally, just as I view my job as the
ultimate sales professional, and every literally almost everyone I touch.
Speaker 2 (33:42):
Oh, it's gross, it's gross.
Speaker 1 (33:50):
Mike Blue is the CEO of Histosonics. Today's show was
produced by Trinamnino and Gabriel Hunter Chang. It was edited
by Alexander Garretson and engineered by Sarah Bruguer. I'm Jacob Goldstein,
and we'll be back next week with another episode of
What's Your Problem.
Pushkin. Hey, it's Jacob. Just a quick note before we
start the show. Today, I'm hosting a new podcast in
addition to this one. The new show is called Business History,
and it's about the history of business and I think
you'll like it. If you like What's Your Problem, I
(00:36):
think you'll like Business History. The first episode is out today.
It's about Southwest Airlines, which is an amazing story. And
then starting next week we're going to have a series
on Thomas Edison, who is really a very What's Your
Problem kind of guy, made an incredible amount of technological progress,
had a really interesting life, lived at an incredible time.
So the show is called Business History. You can listen
(00:58):
to it wherever you are listening to this podcast, Please
check it out. I hope you like it. In twenty seventeen,
Mike Blue was a vice president of sales at Johnson
and Johnson and he went to see a product demonstration
at this little healthcare startup that he was interested in.
It was a small medical device company that was hoping
(01:19):
to use ultrasound in new and dramatic ways, but the
company didn't have any products on the market at the time.
Speaker 2 (01:26):
It was in a garage in Ann arbor. Literally the
office was a dozen or so engineers and they did
a product demonstration for me on the old system that
they delivered this sound energy into a tank of water.
And you see what looks like a hologram. It's the
bubble cloud and it's just suspended in the middle of
the tank and it's just millions of bubbles that are
(01:49):
colliding and collapsing, and it's just suspended there. And they
can move it faster than the eye can detect. They
can stop it, they can start it, like unparalleled control
of it. They can do anything with it. And depending
on who you are, what your lens or perspective is,
I think your mind starts to race as to what
that could mean. I thought, this is gonna be the
(02:10):
best damn sales demonstration in the history of the world.
And I thought, let's just assume it's gonna work. It's effective,
and it's safe no matter where we use it. Oh
my goodness, we're going to sell a ton of these things.
Speaker 1 (02:31):
I'm Jacob Goldstein, and this is what's your problem. My
guest today is Mike Blue. He's the CEO of a
company called Histosonics. The company is developing a technology called histotripsy.
Speaker 2 (02:43):
So many medical terms are in Greek, and so histo
is tissue and tripsy is crushing, the crushing of so
it's the crushing of tissues.
Speaker 1 (02:54):
So histo tripsy, if you speak Greek, it makes perfect sense.
Speaker 2 (03:00):
It's a mouthful for everybody else in English.
Speaker 1 (03:04):
Here's what the company has done. They've taken this histo
tripsy technology that was developed at the University of Michigan
and built a device that shoots multiple ultrasound waves into
the body. At the spot where the waves converge, they
create this cloud of tiny bubbles like the one Mic'
saw in that demo. Those tiny bubbles destroy cells, they
(03:25):
crush tissue. So, for example, you can aim the device
at a tumor inside the body, and if everything goes well,
you can use the bubble cloud to destroy the tumor.
This could be incredibly helpful, especially for tumors that don't
respond well to radiation or chemotherapy or surgery. And in fact,
in twenty twenty three, the FDA cleared the use of
(03:48):
the Histosonics device to treat tumors in the liver. Mike
and I talked a lot about the use of the
device to treat cancer and how Histosonics got there. But
we started by talking about what was happening at the
company when Mike joined in twenty seventeen. This was before
they were focused on cancer treatment, and at the time
(04:09):
they'd run a clinical trial comparing their device with surgery
to treat men with enlarged prostates. But the study found
that surgery worked better to achieve key outcomes. So you
get to the company that the prostate treatment has failed.
Is it already clear that failed? It failed to meet
(04:31):
its primary endpoint. That's the great thing about a trial.
Speaker 2 (04:34):
It is.
Speaker 1 (04:36):
Well, but also it's acceedes or it fails. I'm sticking
with fails.
Speaker 2 (04:42):
When I started and was just getting my teeth kicked
in trying to raise money, I mean, we were a
company running out of money. I mean I was a
bit crazy to take this job. I'll use your term.
We had a failed clinical trial. And you've got a
technology that, or at least a therapy that is almost
too good to be true and unbelievable. And yes, it's
worked in animals, but enough with that animal. Yes, you've
got to become You've got to become a a You've
got to grow up and be a real business.
Speaker 1 (05:03):
And my sly and primates exaggerate, right, that's the and.
Speaker 2 (05:08):
Yes, well said, I was overly confident thought with my
sales background and with an amazing therapy, I would come
in and just raise money. I got my teeth kicked
in for you know, almost two years. And the story
of histotripsy it's to go back to how we open it.
It's hard to say, like, it's not memorable, people can't
remember it, and it's too good to be true, and
(05:28):
you've got this failed clinicaltrure.
Speaker 1 (05:29):
I mean, it's just it was.
Speaker 2 (05:30):
It was hard and so I so we we flipped
the script. We totally changed. We challenged ourselves to find
a story that would resonate, and so we were building
an almost autonomous robotic surgical platform. And if you look
at the evolution of surgery, it's gone from open surgery
(05:50):
to laparoscopic to robotic to our story became we are
developing the future of completely non invasive surgery, which we are,
and robotic non invasive surgery. And the appetite for robotic
investments is incredible.
Speaker 1 (06:07):
So you changed the story, not so much on the
medical side, but on the investor side. It's not saying
so early in the conversation, you don't need to say hist.
Speaker 2 (06:16):
To tripsy, just know that we are going to complete
the evolution of surgical robotics. And so that story led
to an investment from doctor Fred Moule, who's the godfather
of robotic surgery. He was a co founder of Intuitive
Surgical and.
Speaker 1 (06:34):
Sort of the model company for your company.
Speaker 2 (06:36):
It's the poster child for robotic surgery, and he understood. Fortunately,
doctor Mole understood both the robotics of what we were
doing and the therapy.
Speaker 1 (06:47):
Was it already clear that cancer was going to be
the next sort of thing. You tried to make it work.
Speaker 2 (06:55):
So we're blessed to have this ongoing relationship with the
University of Michigan. So there's just incredible professors and researchers
and students who every day get up and work on
the next thing with histotripsy. So at that time, back
now almost ten years ago, there was work being done
(07:16):
specifically on cancers and tumors and small animals, and what
we were learning was that histotripsy is incredibly effective at
destroying cancer cells. And so now I join in January
of twenty seventeen and it's you know, Mike, what do
you think? And so we decided that abdominal tumors is
(07:39):
where we would start. They're the most commonly treated with
other quote unquote interventional devices today, liver, kidney, lung.
Speaker 1 (07:49):
There these are bad cancers to have. I mean, it's
bad to have cancer, but it's really bad to have
the worst.
Speaker 2 (07:56):
I mean liver, liver, lung, and pancreatic, pancreatic being the
worst in terms of five year survival. So we had
made that decision, and then you've got to have discussions
with the FDDA, so we you know, to understand exactly
you've got to align with them on certain things. And
so what we knew we were going to do is
build a robotic platform. We're going to automate the procedure,
(08:19):
democratize the procedure so that you don't have to go
to the absolute best in the world, and because it
can be used anywhere in the body, We're going to
build a platform that can rapidly go from each indication
or application to the next, regardless.
Speaker 1 (08:35):
Of spect You're not going to build a machine to
treat one kind of tumor as well one thing.
Speaker 2 (08:39):
We're building a thing we're building a platform that can
treat a hundred things. You just need to do the
clinical trials. And so we began to work with the
FDA on a broader approach for soft tissue, which is
very common both in interventional devices or for surgical platforms
and robotic systems. A soft tissue indication that allows the
(09:01):
physician to treat any soft tissue or solid tumor that
they deem medically necessary. That's a appropriate Well, there was
keen awareness of histotripsy and how novel it is, how
different it is your liquefying tissue. There's nothing else in
medical device or health care that does.
Speaker 3 (09:20):
This could go not as expected, and there's a different
way that each organ removes that liquification from the bodies
liquified are so in fairness, there's a different risk to
each potential organ, and they asked us to at least
start in a single organ or for a single application.
Speaker 2 (09:43):
So we chose liver based on it. You said, it's
it's still although there's lots of different modalities that are
used in the liver. For liver cancer, five year survival
rates are still less than twenty percent. They really haven't changed,
so you're throwing all this new stuff at it, but
you're still unfortunately, the majority of patients, great majority of
(10:04):
patients are not living over five years. And then, in
addition to that, we want to do in dress because
of all the different ways that you can apply a
non invasive, non toxic therapy, the opportunity is to use
histotripsy in new and novel ways to benefit patients that
just aren't being done today. And that includes the great
(10:25):
majority of patients who not just have primary liver cancer,
but have tumors in their liver that were caused by
their primary cancer.
Speaker 1 (10:37):
So you, for this initial test trial that the FDA
wants you to do, you're gonna treat tumors that are
in the liver, whether they start in the liver or
start somewhere else. You get breast cancer and then it
spreads to your liver for example.
Speaker 2 (10:50):
That's it, yep, And we're gonna we're gonna treat those
tumors and we're going to demonstrate that we can do
it safely and we can effectively destroy any tumor from
any origin that is in the liver. And that was
the primary objective or aim of the hope for Liver study,
which was our pivotal clinical study for the FDA.
Speaker 1 (11:11):
Right, so let's talk about that study, the Hope for
Liver study, Like, who was it, what was the endpoint,
what were the patients?
Speaker 2 (11:21):
So, when you're working with the FDA on designing these studies,
it is very collaborative. There are things that you want
as a company and propose and work through, and then
there are things that the agency ultimately requires a few
And because this is a new novel therapy never been
done before, especially in a cancerous tumor, they required that
(11:46):
we treat patients who were had either failed all other
treatment options or intolerable, meaning they just they just they
hadn't failed surgery or radiation, they just can't they can't
tolerate it be based on their overall condition.
Speaker 1 (12:03):
Basically people who don't have any other options, who are
typically quite so.
Speaker 2 (12:06):
So yeah, and when we set the inclusion exclusion criteria,
we had not envisioned that that would be.
Speaker 1 (12:14):
Well, that's how they do drugs, right. If you have
a new drug, then the FDA says, well, make sure
that patients have already tried the drugs that we already
know work. Right, It seems quite analogous.
Speaker 2 (12:23):
Very analogous and in some respects fair and so yeah,
so we were required to treat advanced, very advanced stage patients.
The challenge with that is that when we set our
safety goal and our efficacy goal, we set that based
on the data that's available and on and the data
(12:44):
that's available is on much healthier patients, usually earlier stage
patients with curative intent. And we didn't change the the
end points were, what the performance criteria was that we
had established. We could only change who these patients were
that we were treating. Why not, Well, that's not you
don't necessarily get to site all the rules when you're
(13:05):
negotiating with the agency, and so it's just a requirement
that we ended up having to live by.
Speaker 1 (13:09):
So just the basics of the trial, like how many patients,
what's the outcome? You know, what's the basics there.
Speaker 2 (13:17):
So we negotiated a study that would enroll I think
it was up to fifty patients. We ended up I
think we enrolled forty four and with pretty acute outcomes
both in terms of safety and efficacy.
Speaker 1 (13:34):
And what was the result, What were the results?
Speaker 2 (13:36):
So they were incredibly positive. In fact, now we've published
our one year data, and honestly, I didn't know that
a year out or two years out the data would
be very interesting at all. These were super sick patients
and again we're measuring it the performance criterias against healthier patients,
and so if you could get anywhere close at one year,
(14:00):
you know, I thought we'd be doing pretty good, but
I doubted that. But that's where we ended up. We
just published our one year follow up data on the
patients who have local tumor control, meaning meaning it's still
dead ninety percent of the time in those patients, which
rivals any other therapy that's being delivered in delivered today.
Speaker 1 (14:22):
And just to be clear, when you say it's still dead,
do you mean the whole tumor is gone. I mean
it doesn't mean they don't have cancer anymore. Right, This
doesn't like these are super sick patients. You didn't just
cure their cancer.
Speaker 2 (14:33):
Just to be clear, the aim of the study was
to show that we can safely target and destroy a
tumor and that that tumor does not come back. The
aim of the study was not to show that we're
extending their life, we're improving their overall survival, which is
obviously a really important metric in cancer care, and ultimately
we will do that.
Speaker 1 (14:51):
It's ultimately the one we care. I mean, I suppose
there's quality of life as well, but neither of these
is a clinical measure, right.
Speaker 2 (14:58):
And I would argue today now that we're a year
and a half into our true clinical experience, what I
call the real world rout the wild being used in
an unbelievable number of different ways and use cases. Improving
quality of life is probably the number one thing that
I think we're just so excited about. It's just it's unbelievable.
Speaker 1 (15:18):
I want to talk about that. I want to talk
about a lot of stuff besides the study, but just
to finish on the study, Yeah, just the dumb question
you're saying, you killed the tumor, why does the person
still have cancer?
Speaker 2 (15:29):
Because for most of the patients we treated, again based
on the requirement that the FDA established, they had lots
of tumors. They had what they call multifocal disease. So
not just two or three, we're talking half a dozen dozen.
Many of the patients had dozens of tumors and the
(15:51):
protocol allowed for the treatment of up to three. So
we know most of those patients, the great majority had
tumors beyond what we were treating.
Speaker 1 (16:03):
The one other endpoint you were monitoring was serious adverse
events related to the right. What was the outcome for that?
Speaker 2 (16:11):
Yep, I think there were three grade three or higher ctcas,
which is how one of the models they used to
score serious adverse events. So there were three of them
out of the forty four patients, which far exceeded our
primary endpoint. And again the primary end point was measured
(16:34):
against much healthier patients, so you had far fewer serious
adverse events than you would expect and are measured against
healthier patients. So incredibly excited about how safe this procedure
is in a sicker patient patient.
Speaker 1 (16:51):
I thought it was six.
Speaker 2 (16:52):
There were three that were grade three higher.
Speaker 1 (16:56):
I don't know the grade three. I just thought there
were six serious adverse device.
Speaker 2 (17:00):
The six in total.
Speaker 1 (17:02):
Thank you for going into the weeds with me. Now
we can come back out.
Speaker 2 (17:06):
Not what I expected. I love it.
Speaker 1 (17:12):
After a break, we'll come back out of the weeds.
So where are your devices in the world now? Like,
are they out there? Are people buying them? Are doctors
using them in the real world? Now?
Speaker 2 (17:33):
I mean this has been a long, long journey. A
glorious Friday, October sixth of twenty twenty three that we
finally had the email come across that awarded us at
Denovo grant or a clearance to begin commercializing the Edison
system and the use of histotripsy and the liver.
Speaker 1 (17:55):
This is the email from the FDA, an email from
the FDA.
Speaker 2 (17:59):
So we've got a gong in the building that is
called the getting Shit done gong, and we hit the
hell out of that gong and an awesome party immense
upon receiving that letter. I mean, it's just you know,
it is the pinnacle milestone for any healthcare company, and
so a first in my career. Within one hour after
(18:20):
that announcement, we had our first purchase order for an
Edison system.
Speaker 1 (18:25):
The one hour was it just waiting? Was it?
Speaker 2 (18:27):
Was?
Speaker 1 (18:27):
It just like you had the contract.
Speaker 2 (18:29):
They were waiting. We had. We had a very small
skeleton crew of sales professionals who are out socialized in
the contrast concept of histotripsy and and what it could
mean to physicians, patients and hospitals and so uh, the
Cleveland Clinic was locked and loaded and ready to claim
(18:49):
that they were the first in the world to begin
using histo tripsy for their their livertub er patients.
Speaker 1 (18:56):
And so how does the University of Michigan feel about
getting scooped on its own technology.
Speaker 2 (19:00):
Yeah, yeah, it didn't go over so well.
Speaker 1 (19:02):
Were they were they number two? Do they have one?
Speaker 4 (19:04):
Now?
Speaker 2 (19:05):
They were not number two? They were they were within
the top and now they have multiple within within.
Speaker 1 (19:13):
How many of them are out in the world now?
How many of yes?
Speaker 2 (19:16):
You know. A year and a half into commercializing, the
thought was it was almost exclusively be in the US.
We're now in the process of a scheduling delivery of
our one hundred system.
Speaker 1 (19:26):
One hundred okay, so a lot a non trivial number.
Speaker 2 (19:29):
You know, if you compare it to other historic commercial
launches of a robotic medical device or platform, we're far
exceeding expectations. And the patient demand for this is is
like nothing I've ever been a part of and what
we had hoped for. It's sad and that there's so
many patients who are told their terminal because now they
(19:51):
have tumors in their liver that can't be treated. They're
adjacent to a bile duct, they're just too large there's
just too many of them. There's no drugs that work
for these tumors once they're in their liver, and we
can treat these patients and we can do it without toxicity,
without side effects.
Speaker 1 (20:05):
I mean, there is some pain right like related with
the treatment.
Speaker 2 (20:09):
So they'll there will be discomfort because a lot of
times you're treating over the rib cage that they explain
it usually as they've done too many sit ups the
day before, like that, that sort of pain. Some of
them have flu like symptoms, which is symptomatic of potentially
the immune system being revved up. But beyond that nothing
(20:32):
like an invasive procedure or radiation therapy, you can't even
compare them.
Speaker 1 (20:38):
So if I if I walk into a room where
your device is, like, what's it look like?
Speaker 4 (20:45):
Like?
Speaker 1 (20:45):
Let's just talk about how it works. What do I
see when I walk down the room?
Speaker 2 (20:51):
Yep, you see what looks like a medical device system
with a It's pretty noticeable. It's got a pretty large
robotic arm that is used to guide the therapy. It's
got a very obvious forty two inch high fidelity touchscreen display.
So you see a cart that's I guess similar to
(21:14):
what you'd think of like an ultrasound cart. That's where
all the work is done, and then you've got a
robotic arm that comes off that that steers the histotripsy.
Because it's non invasive, it doesn't require a sterile environment,
so you definitely don't need to be in an operating room.
It doesn't even require a clean room. You can virtually
do procedures in any room. And ultimately the vision is
(21:37):
it'll be used by an incredible number of specialists or specialties.
So that's what it looks like.
Speaker 1 (21:44):
So let's say, so there's a procedure, what happens, there's
a doctor, there's a patient, like, where are they?
Speaker 2 (21:49):
What happened? Like every robotic procedure being done in the
hospital setting today, the patient usually not always anymore, but
usually under general anesthesia. The reason for that is not pain.
It's about limiting motion. So, because we're delivering this beam therapy,
we don't want the patient moving, we don't want the
(22:09):
organ moving, we don't want the tumor.
Speaker 1 (22:11):
Moving like you're targeting like a centimeter, right, I.
Speaker 2 (22:14):
Mean it's the yeah, the point on a pencil tip.
Speaker 1 (22:18):
Breathing, So does breathing mess you up?
Speaker 2 (22:20):
Right? And so where we are today treating in the liver,
finishing our study on kidney tumors, beginning our studies on
pancreatic tumors. These organs and therefore tumors move because of
the diaph the movement of the diaphragm.
Speaker 1 (22:36):
What do you do about that? Like? That isn't I mean?
Do you account for it? Do you predict where it's
going to be based on the breath?
Speaker 4 (22:43):
Like?
Speaker 1 (22:43):
How do you deal with that?
Speaker 2 (22:44):
That's why you use general anthesus because the anithesiologists then
can absolutely control motion.
Speaker 1 (22:51):
Oh so you say to the anesthesiologists, halt the breathing
for one second. I'm going to shoot the beam.
Speaker 2 (22:58):
It doesn't have to be completely still. Almost all of
them there's some motion, and we just, huh what they
call envelope around that. So we just create you know,
if you've got a one centimeter tumor, you create a
two centimeter target so that the motion of the your
targeted area still encompasses the tumor, even if even if
(23:19):
it's moving.
Speaker 1 (23:20):
So okay, so the patient's under general anesthesis, so they
don't move too much.
Speaker 2 (23:23):
Go on, Yeah, so there's still there's still and then
you watch the physician operate on that again super high
fidelity touchscreen display. There is a step to the planning
process where we send in planning pulses to seven discrete
points within the targeted area, both within the tumor and
just outside. And the reason for that is depending on
(23:48):
how much blockage there is, if it's under a rib,
if it's under a bow, or if it's completely unobstructed,
there's a different level of energy that is needed to
destroy different areas within even sometimes the same tumor, but
definitely if you're treating multiple tumors, one could be directly
under a rib totally obstructed, one could be totally unobstructed.
(24:10):
The variability then between how much energy the system needs
the delivers it can be pretty significant. And then once
they begin or initiate therapy, the robot has the ability
to dynamically change the energy requirements throughout the treated volume
based on that treatment map. So you watch that, you're
(24:31):
literally watching the physician work at the console do their
work there, and then there's a button that says enable treatment,
and once everyone agrees they've they've set the plan. The
system knows how much energy it needs to deliver and augment,
they enable therapy and then it's all visualization. It's it's
just monitoring.
Speaker 1 (24:51):
So once they enable therapy, like what happens with the
robot arm, what does it do? And like where's the
ultrasound coming out of?
Speaker 2 (24:58):
It goes to work. So it's the workhorse. It begins.
It's got these amazing it's it's so elegant to watch.
They've got incredibly fine smooth motions that are moving that.
So think of the histo tripsy cloud the size of
a grain of rice. It's super small and it's got
to go through a large volume. So it does all
(25:19):
the work moving that bubble cloud until it's completely destroyed.
Speaker 1 (25:23):
And just to be clear, it's destroying the tumor at
a cellular level, right, the reason you're not spreading the
cancer around the body.
Speaker 2 (25:31):
It's actually subcellular destruction. It's if you were to show
it to a pathologist, we show or when a pathologist
reads that liquefied tissue coming from an app they'll tell
you it's unrecognizable. There's no cellular debris. They couldn't tell
you forget about is it benign, or they can't tell
(25:52):
you if it's liver, kidney anchoras brain. It's just a
liquefied acellular debris that is unrecoible go. It's literally a goo,
even more soluble than a goo, A.
Speaker 1 (26:06):
Thin, very thin that is. And then it's done. And
then the procedure is done.
Speaker 2 (26:13):
Yeah, they awake from their anesthesia, hopefully they feel like
nothing has happened, and they go home.
Speaker 1 (26:19):
So you have this indication for any liver tumor. What
else are you working on beyond liver tumors?
Speaker 2 (26:27):
We are now realizing the vision of the researchers who
invented histor tripsy and when the company was founded, moving
as fast as we can into other clinical applications. And
so we've finished in rolling patients in our kidney tumor trial.
We will have the data back from that here shortly
(26:47):
and be submitting for histor tripsy of kidney cancer in
Q one of twenty twenty six. We've begun in rolling
patients in a pancreatic tumor trial that's being done in Barcelona, Spain.
We are working with the agency as we speak to
(27:08):
arrive on a call for the US study treating pancreatic
tumors with hista tripsy. I really do believe it's gonna
be groundbreaking.
Speaker 1 (27:15):
What are you trying to figure out now? Like, what
is a use case where you haven't kind of quite
solved all the things you need to solve to make
it work.
Speaker 2 (27:24):
There's very little clinically and technically. It's the challenges that
come with such a high growth company and adding so
many people. And I think if you I'll invite you
to visit us, I think we'll give you a demo
so we can make all this real.
Speaker 1 (27:43):
I want the demo. After you describe the demo.
Speaker 2 (27:46):
You have to have the demo. I think, you know,
I'm very proud that whomever is visiting here, they immediately
notice the people, the culture of the vibe, the tech
permeates throughout. Super innovative company with great people, smart people
but are having fun. Literally you know, change the world.
(28:09):
And so it's it's preserving that as we grow at
a unusually fast pace and at a significant number of
people moving forward, is there such an unmet clinical need
that we can address. And as I as I say
to our team we've got a town hall tomorrow, I'll
you know, I always remind them that I know we
said unusually aggressive objectives, and I will not apologize. There
(28:31):
is a patient who is suffering in every one of
the diseases that we can impact, and we have to
go faster. It's it's literally it's the first company I've
ever been with, right, I feel like we actually have
a I use this word a lot, or we have
a responsibility the faster we can move and kidney pancreas,
prostate brain diary, breast bladder. There's patients who need us
today and we won't be there in time unfortunately for
(28:52):
all of them. So it's our responsibility to go faster.
So that's kind of stuff that keeps me up at night.
Speaker 1 (29:01):
We'll be back in a minute with the lightning round.
We're going to do a sales focus lightning round because
I know that you spent your career in sales and
that was all we could figure out about you. Is
(29:22):
there anything that you had to sort of unlearn from
your life in sales to be a good CEO? Any
like habits of the sales mind that don't serve you
well as a CEO.
Speaker 2 (29:33):
So at one point in my career, before I joined
his Tosonics, obviously I really doubted I wanted to be
a CEO. I didn't know if I could get the
same gratification statis satisfication. That's not our word gratification.
Speaker 1 (29:48):
I like satisfication. That's when gratification meets satisfaction too. Actually,
the ginormous of satisfaction.
Speaker 2 (29:54):
I just didn't know if I could get that same gratification,
like the rush of I love to win. I love
closing a deal. I love to win. I hate losing
even more. And that's what you get in sales. You're
out every day competing against your peers, other companies. So
I thought coming into this I would have to temper
my excitement for the thrill of the win and the
(30:17):
hatred for the loss. But I think what's helped the
company is I haven't done that. Like, you can apply
the same winning and losing philosophies across every function within
the organization. I want to win with the FDA, I
hate losing. I hate needing to renegotiate, I hate the delay.
(30:37):
And you can literally apply that that logic across or
dispe It works everywhere.
Speaker 1 (30:45):
It works.
Speaker 2 (30:47):
Everywhere. Okay, fair enough, Look you if you bring that
to work every day, like you know, like I tell
my kids, if you find something you genuinely love a
company that you genuinely believe in, and you go out
and work your ass off every day and you compete,
Like at what I just said. And then third, and
I hope if you were to walk through this building,
what you would see is amazing human beings. Like that's recipe, Like, Yeah,
(31:10):
find something you love and you're passionate for a company
you believe in what they're doing, work your ass off,
compete to win, hate to lose, and you're a genuinely
good human being. And that's how you treat everybody. There's
really nothing else. There's nothing more to success in industry
than that.
Speaker 1 (31:27):
What's the hardest thing you ever had to sell?
Speaker 2 (31:30):
Well, I think I'm good at selling everything.
Speaker 1 (31:33):
I didn't say, what were you bad at selling?
Speaker 2 (31:35):
Like?
Speaker 1 (31:35):
I just said what was hard?
Speaker 2 (31:37):
I will so I will say this, I would make
a horrible venture capitalist, like horrible.
Speaker 1 (31:45):
Interesting. Well, in a way, they're on the buying side, right,
I mean, I'm sure they're selling themselves to the hot
founder or whatever, but.
Speaker 2 (31:52):
They're evaluating all these opportunities in which ones they're going
to invest in, and they choose one out of one
hundred to invest in. My problem is I always look
at them with the perspective or with the lens of
could I sell this? And I'm an overly confident person
that I look about just everything and say, oh, I
could sell that. And so I'd be a horrible venture
(32:14):
capitalist the heart.
Speaker 1 (32:15):
Because you'd invest in everybody because you'd be like, yeah,
sure I could sell that whatever, I'll flip it for
ten X.
Speaker 2 (32:20):
Yeah we could do we could do that. The problem
is if you're not the one doing that, then you're
relying on someone else. You don't have the control of
what they're doing day to day.
Speaker 1 (32:31):
You know.
Speaker 2 (32:31):
I Selling medical technology is hard. It's just it is.
It's just really hard. Especially in today's healthcare environment. Just
getting access into hospitals has become so complex. So it
doesn't matter whether you're selling a single use widget or
a two million dollar robotic platform. It's changing the world.
Speaker 1 (32:55):
It's by the way, is it two million dollars? I
didn't ask you how much does it cost? Is the answer?
Two million dollars.
Speaker 2 (32:59):
It's not. It's not two million dollars. But what we
generally say is it compares very favorably to the other
high end surgical robotic platforms.
Speaker 1 (33:09):
Fine, I just wanted some ballpark.
Speaker 2 (33:11):
Call it a million, million, million and a half dollars.
That's fun.
Speaker 1 (33:14):
Okay, great, last one.
Speaker 2 (33:17):
Uh.
Speaker 1 (33:18):
I'm curious as a as a person who knows sales
so well, when you're on the other end of sales,
when you're a buyer, say, when you go buy a car,
what is it like for you?
Speaker 2 (33:28):
It's bullshit.
Speaker 4 (33:29):
It's like there's nothing worse, And it's everywhere in this world,
like literally, just as I view my job as the
ultimate sales professional, and every literally almost everyone I touch.
Speaker 2 (33:42):
Oh, it's gross, it's gross.
Speaker 1 (33:50):
Mike Blue is the CEO of Histosonics. Today's show was
produced by Trinamnino and Gabriel Hunter Chang. It was edited
by Alexander Garretson and engineered by Sarah Bruguer. I'm Jacob Goldstein,
and we'll be back next week with another episode of
What's Your Problem.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Ruthie's Table 4
For more than 30 years The River Cafe in London, has been the home-from-home of artists, architects, designers, actors, collectors, writers, activists, and politicians. Michael Caine, Glenn Close, JJ Abrams, Steve McQueen, Victoria and David Beckham, and Lily Allen, are just some of the people who love to call The River Cafe home. On River Cafe Table 4, Rogers sits down with her customers—who have become friends—to talk about food memories. Table 4 explores how food impacts every aspect of our lives. “Foods is politics, food is cultural, food is how you express love, food is about your heritage, it defines who you and who you want to be,” says Rogers. Each week, Rogers invites her guest to reminisce about family suppers and first dates, what they cook, how they eat when performing, the restaurants they choose, and what food they seek when they need comfort. And to punctuate each episode of Table 4, guests such as Ralph Fiennes, Emily Blunt, and Alfonso Cuarón, read their favourite recipe from one of the best-selling River Cafe cookbooks. Table 4 itself, is situated near The River Cafe’s open kitchen, close to the bright pink wood-fired oven and next to the glossy yellow pass, where Ruthie oversees the restaurant. You are invited to take a seat at this intimate table and join the conversation. For more information, recipes, and ingredients, go to https://shoptherivercafe.co.uk/ Web: https://rivercafe.co.uk/ Instagram: www.instagram.com/therivercafelondon/ Facebook: https://en-gb.facebook.com/therivercafelondon/ For more podcasts from iHeartRadio, visit the iheartradio app, apple podcasts, or wherever you listen to your favorite shows. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com